企業プロフィール
Arcutis Biotherapeutics 株価・ニュース・カタリスト
- ティッカー:
- ARQT
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
25.61 USD (-2.21%)
終値
最終更新: 2026年8月17日
2.6B USD
時価総額
株価変動の要因
As of Aug 17, 2026, ARQT closed down 2.21% at $25.61. No new same-company headline was identified in the current news window.
企業概要
Medical Dermatology
Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology.
ZORYVE Franchise
ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic dermatitis and seborrheic dermatitis.
Pediatric Expansion
Arcutis is seeking to extend ZORYVE cream to infants with atopic dermatitis and ZORYVE foam to younger children with scalp and body plaque psoriasis.
New ZORYVE Indications
Phase 2 proof-of-concept studies are evaluating ZORYVE foam in vitiligo and hidradenitis suppurativa.
ARQ-234
ARQ-234 is a biologic candidate in initial clinical development for moderate-to-severe atopic dermatitis, expanding Arcutis beyond topical PDE4 inhibition.
今後のカタリスト
- FDA review milestones for the ZORYVE cream infant-atopic-dermatitis sNDA.
- Phase 2 vitiligo results and an advancement decision in the fourth quarter of 2026.
- Phase 2 hidradenitis-suppurativa results and an advancement decision in the first quarter of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。